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I. INTRODUCTION  
Long-term parenteral nutrition is an essential therapy for patients with 
intestinal failure. The major causes of intestinal failure are short bowel syndrome, 
Crohn’s disease, pseudo-obstruction, radiation enteritis and enterocutaneous 
fistulae(1). Despite its noticeable benefits, long-term parenteral nutrition (PN) is 
associated with significant complications such as infection, inflammation, liver 
dysfunction, bacteria translocation, metabolic and electrolyte disturbances, whose 
physiopathology is not well understood mainly due to scarce experience. We 
present a case report of a 42-year-old woman, exclusively under total home 
parenteral nutritional (HPN) for 10 years, after being subjected to subtotal 
enterectomy plus colectomy due to intestinal ischemia, that later developed 
seronegative arthritis, liver dysfunction and metabolic bone disease. The authors 
discuss the diagnostic possibilities and physiopathology underlying the patients’ 
clinical manifestations, as well as its management challenges. 
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II. CASE DESCRIPTION  
A previously healthy 32-year-old woman was admitted to the emergency 
department in 2008 with acute abdomen, three weeks following her first child’s 
uncomplicated eutocic delivery. The exploratory laparotomy uncovered a midgut 
volvulus with infarction of the small intestine, cecum and ileocecal valve, leading 
to a subtotal enterectomy (only the duodenum and 2 cm of jejunum was left) and 
colectomy of the cecum and a portion of the ascending colon. Inflammatory bowel 
disease was excluded. The resulting intestinal failure lead to long-term PN 
requirement. Since then, several complications have developed, most of them 
associated with the long-term HPN therapy.  
Regarding the constitution of the HPN bag, it includes: Nutriflex Lipid Specialâ, 
Adamelâ, Vitalipidâ, Soluvitâ, Glycophus, magnesium sulphate, zinc and calcium 
gluconate.  
Despite total PN, the patient sustained oral consumption of food regularly. 
Some episodes of abdominal pain with watery diarrhea were often reported. A 
recent colonoscopy progressed to duodenum and revealed no relevant findings. 
Several episodes of catheter-associated infections and septicemia have 
occurred, justifying hospital admission for parental antibiotics. However, no 
infectious episodes have occurred in the last 7 years.  
Cholestatic jaundice with subsequent coagulopathy and dyslipidemia was also 
detected in the first months of HPN. Both alanine transaminase (ALT) and aspartate 
transaminase (AST) were consistently high since 2008, although currently normal. 
Four months after total HPN initiation, a liver biopsy showed cholestasis, periportal 
space bile thrombus, fibrosis, formation of septa and proliferation of new ducts 
with lymphoplasmocytic inflammatory infiltrate in the periportal space and focal 
signs of necroinflammatory activity. No significant steatosis was present. Viral and 
autoimmune hepatitis were excluded. 
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Progressive osteoporosis has been detected in densitometries since 2009 
(lower spine T increased from -2.5 to -3.3; femur T -0.9 to -2.6) despite parenteral 
ergocalciferol and paricalcitol and high doses of oral cholecalciferol. Serum levels 
of 25-hydroxivitamin D are consistently low or undetectable since 2008. In 2015, 
she had multiple osteoporotic vertebral fractures (in D5, D12, L1, L2, L3 and L4) 
with aggravated lower back pain. Kidney function, serum total calcium and 
phosphorous levels have always been normal. Parathyroid hormone (PTH) serum 
levels were at first low, but since the end of 2014 they spiked to approximately 
twice the upper limit (100-160; N:15-65), with no possible relation with the dosing 
of paricalcitol. Parathyroid scintigraphy excluded primary pathology of the glands. 
In April 2014, the patient presented with symmetric polyarthritis of the small 
and large joints and morning stiffness lasting for more than 2 hours, limiting the 
patient’s ability to prepare the PN bag. A magnetic resonance of the hands imaging 
showed wrists synovitis with no proliferation or bone erosions. Laboratory tests 
revealed a persistent inflammatory state: long-term normocytic normochromic 
anemia (which has normalized in 2015); isolated hyperferritinemia since 2008 
(median=1757; reference values=2.20-178ng/mL); erythrocyte sedimentation 
rate (median=26; reference values= 0-19 mm/h) and C-reactive protein 
(median=1.03; reference values= 0-5.0 mg/L) have always been slightly elevated.  
The patient is seronegative for rheumatoid factor, anti-citrullinated protein, 
anti-neutrophils cytoplasm (ANCA), anti-Saccaromyces cerevisiae (ASCA), anti-
nuclear, anti-double stranded DNA, anti-Sm, anti-U1 RNP, Anti-SS-A/Ro and Anti-
SS-B/La autoantibodies. Immunoglobulin G level is high (2237mg/dL); serum 
complement C3 and C4 levels are normal.  
A partial response was obtained with 10mg/morning of prednisolone, and later 
azathioprine (AZA) 50 mg/day was added (primarily absorbed in the stomach, 
jejunum and cecum). However, since there was insufficient clinical response, AZA 
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was switched for methotrexate (MTX) 10-15 mg subcutaneous/week with 
improvement but no complete remission. In order to reduce MTX dosing (due to 
liver profile and relative contraindication) sulfasalazine (SLZ) (500mg+500mg) was 
introduced. The patient’s remarkable clinical response to SLZ, allowed the steroid 
dose tapering for the first time.  
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III. DISCUSSION BASED ON LITERATURE REVIEW 
 
i. Parental Nutrition 
The use of PN is a well-established therapy that results in long-term survival 
of patients with intestinal failure. Although the value of this life-sustaining 
treatment is clear, there are potential negative outcomes associated with this 
therapy. Complications can be infectious, mechanical, or metabolic, although it is 
unclear if they are due to the PN treatment per se or associated to the diseases that 
lead to the intestinal insufficiency. In general, however, the pathogenesis of PN 
associated diseases is currently considered to be multifactorial and a patient-
dependent phenomenon (cause and extent of short bowel syndrome, bacterial 
translocation, and nutritional factors)(2). 
Data on patient outcomes has been difficult to collect, as there is no 
prospective database of patients on HPN. Mullady DK et al refers to a 20-year 
experience database at the Mayo Clinic with 255 HPN patients in 1999. In this 
study, the overall probability of the 5-year survival during HPN was 60%. Probability 
of survival correlated with the underlying disease process and with age – young 
patients had an improved survival rate. Death from TPN-related complications is 
generally rare but can occur from catheter-related sepsis (1).  
 
ii. Inflammation and immune function in HPN patients 
One hypothesis to explain PN-associated disease is that a permanent chronic 
inflammatory status exists among these patients, based on animal studies and few 
human studies confirming that HPN leads to a low-level, chronic, inflammatory 
response. The lack of significant small intestinal mass (as in short bowel syndrome) 
or the absence of small intestine stimulation through normal enteral feeding could 
lead to the increase level of inflammation or immune impairment observed on HPN 
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patients. Alternatively, component(s) of the PN solution could lead to these results, 
and each condition could interact and exacerbate the other(3). 
 
iii. Catheter-related infections 
Catheter-related infection is the most common complication and major cause 
of morbidity among patients on HPN; it accounts for approximately 70% of HPN-
related hospitalizations(1). The occurrence of several episodes of sepsis on PN 
patients increases the possibility of metastatic infection from the primary 
parenteral nutrition line. Our patient had several episodes of catheter-associated 
infections and bacteremia; however, these have not occurred in the last 7 years, 
making it an unlikely explanation for the patient’s most recent clinical 
manifestations.  
 
iv. Hepatobiliary disorders 
Intestinal failure-associated liver disease (IFALD) is the hepatic dysfunction that 
occurs secondary to intestinal failure in the presence of PN. In adults, the major 
types of total HPN-associated liver disease are intrahepatic cholestasis, steatosis 
(microvesicular and macrovesicular), steatohepatitis and cholecystitis; however, 
overlap can exist.  
Although the patient’s liver histologic findings were compatible with 
autoimmune hepatitis (AIH), the biopsy was performed early after several metabolic 
and inflammatory events, and beside hypergammaglobulinemia, no other findings 
were compatible with AIH and no change occurred with immunosuppressive 
treatment.  
Persistent inflammation and immune activation have been suggested as 
contributors to chronic cholestasis in patients who receive HPN(4). Although arthritis 
has not been described associated with IFLAD, inflammation establishes a possible 
relation between them. In one study, a subset of patients with extreme short bowel 
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without an associated inflammatory disorder, had no evidence of liver disease after 
an average of 13.6 ± 6.7 years of HPN(5). This suggest that it is the presence of an 
associated underlying inflammatory disorder, rather than simply the remaining 
length of small intestine, that poses the greatest risk for the development of end-
stage liver disease.  
 
v. Metabolic Bone Disease 
The bone metabolism disturbances associated to PN have been extensively 
described. It manifests as either osteomalacia with excessive organic bone matrix, 
but deficient calcification or osteoid tissue, or osteoporosis with decreased bone 
mass characterized by an increase in the ratio of bone formation, and a normal 
ratio of mineral to organic constituents. A combination of osteomalacia and 
osteoporosis may also be observed. It is unknown how long a patient must be on 
total PN before bone disease becomes evident(6).  
Most cases of PN-associated metabolic bone disease (PN-MBD) relate to 
abnormalities in the handling of calcium, phosphorus, vitamin D and K, as well as 
underlying medical conditions such as Crohn’s disease. Patients with PN-MBD may 
present with bone pain and bone fractures with minimal or no trauma; but, most 
are asymptomatic. Biochemical parameters associated with bone formation and 
mineralization are often normal. In some cases, an elevation in urinary calcium, 
and an increase in serum calcium, phosphorous and alkaline phosphatase may 
occur(7). 
An iatrogenic adynamic bone disease related to excessive paricalcitol 
administration is a hypothesis to be considered. The patients underlying 
inflammatory state also contributes to this metabolic bone disease.  
Our patient presents vitamin D deficiency and hyperparathyroidism despite 
receiving high doses of oral cholecalciferol, paricalcitol IV and ergocalciferol in the 
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PN bag. Paricalcitol, an analog of 1,25-dihydroxyergocalciferol, acts as an agonist 
at the vitamin D receptor and thereby lowers parathyroid hormone levels in the 
blood. However, the patient’s PTH does not seem to suppress despite high doses 
of this drug. Paricalcitol is traditionally prescribed to treat secondary 
hyperparathyroidism in chronic kidney disease patients; its efficacy and side-
effects in patients under HPN is unknown.  
The absence of bone biopsy, the persistent inflammatory state and the 
maintenance of oral intake by the patient makes its interpretation rather complex.  
Systemic inflammation and chronically high levels of circulating cytokines 
interact with bone through multiple pathways, synergizing to produce profound 
net bone loss. This interaction between inflammation and bone loss, typically 
observed in patients with rheumatoid arthritis (RA), clinically reflects the molecular 
and cellular interactions between the immune system and the bone, also known as 
osteoimmunology. This makes the initial hypothesis of an association of long-term 
PN use with chronic inflammatory sequelae and a potential for associated immune 
dysfunction one that must be considered.  
 
vi. Joint inflammatory disease  
Following jejunoileal bypass, rheumatic manifestations develop in up to 20% of 
cases. When Dicken and Seehafer reported for the first time in 1979 a condition 
named bowel bypass syndrome (BBS) (characterized by recurrent episodes of fever, 
malaise, nonerosive polyarthralgia or arthritis, and the development of skin 
lesions), one of the most likely hypothesis was bacterial overgrowth in a blind loop 
syndrome(8).  
The complex interactions between the gut microbiota and the modified 
intestinal environment in PN patients is crucial for understanding the joint-gut 
 9 
 
dysbiosis axis, which has been described particularly in patients with Inflammatory 
Bowel Disease. The PN-associated proinflammatory state within the intestinal 
epithelium and resulting loss of the epithelial barrier function promotes the 
susceptibility of the epithelial barrier to enteroinvasion and translocation of 
microbiota-derived products. There is increasing evidence that the PN-dependent 
state leads to primary significant shift in the makeup of the intestinal 
microbiome(9). To date, limited data regarding the impact of PN on the human 
intestinal microbiome is available.  
Mechanisms by which intestinal microbiota contribute to initiation or severity 
of autoimmunity are varied. Recently, investigators have focused on the gut 
microbiota, which is thought to be an environmental agent affecting the 
development RA. A study by Pianta et at provides new evidence that the 
pathogenesis of RA may involve molecular mimicry(10). Molecular mimicry is one 
mechanism by which dysbiosis can impact the pathogenesis of autoimmunity. 
Genetic factors may affect the composition of the microbiome; dysbiosis may 
perturb the poise of the immune system; and inflammation may lead to dysbiosis. 
The interplay between host and organism is thus likely to be complicated and 
dynamic.  
Inflammation is a plausible explanation for the patient’s clinical manifestations 
as shown by analytic findings and the clinical response to immunosuppression. The 
association between bone disease and arthritis is well established in RA but this 
patient presents a seronegative non-erosive arthritis, so this hypothesis in unlikely. 
The inflammatory etiology for her arthritis seems to be the most probable, 
although the trigger of this process is not known.  
The previous intestinal surgery by itself could cause a blind-loop syndrome but 
the gap between surgery and the arthritis is too long. It could be a BBS, through 
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bacterial overgrowth in the remnant intestine, but no skin lesions have been found. 
Another hypothesis is a pre-existent underlying subclinical process that could be 
having clinical manifestations just now. Inflammatory Bowel Disease, like Crohn’s 
Disease, could aggregate and explain the clinical manifestations found, having the 
patients shown remarkable response to SLZ. However, it seems unlikely due to the 
normal colonoscopy, but further investigation is needed. SLZ is an intestinal 
immunomodulator used to treatment of Inflammatory Bowel Disease, as well as 
other inflammatory arthritis; we could hypothesize that the remarkable clinical 
response to SLZ supports the hypothesis of underlying intestinal dysbiosis as a 
trigger for an autoimmune process. 
 
vii. Limitations of the case 
To clarify the bone disease etiology, a bone biopsy would be necessary. 
Additionally, microbiota characterization of the intestinal population would be of 
great value but very few laboratories perform it and there is scarce data for its 
interpretation. A longer follow-up time will also be of the upmost importance, as 
further symptomatic manifestations may clarify the etiology of the underlying 
disease. 
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IV. CONCLUSION 
Long-term parenteral nutrition follow-up is limited, so the knowledge of 
associated diseases and complications are still in early stages of being described 
and understood. It is important to remember that PN is an unphysiologic route of 
nutrient supply that bypasses the gastrointestinal tract and portal system, making 
the effects of continuously administering of these nutrients directly into venous 
blood largely unknown. We described a clinical case of a female patient submitted 
to long-term HPN and several associated co-morbilities such as bone associated 
disease and hepatic disorder. More recently, a less understood arthritis developed, 
resistant to AZA and largely responsive to SLZ. A common etiopathological 
explanation to aggregate most of the patient’s manifestations was hypothesized.  
This case report will shed new light on the possible pathogenic effects of long-
term exposure to this life-saving therapy. Since there is limited knowledge 
regarding the long-term impact and management of HPN patients due to lack of 
research in this area, additional studies are required.  
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